ࡱ> JLIc bjbjԚ 2*Z\Z\ > JJJJJ^^^8<^.(:PPPp.r.r.r.r.r.r.$03.JF@.JJPP.JPJPp.p.,|,.P  Fx-\..0.-g4f:g4$,.g4J,.0...g4 > : 51 Institutional Biosafety Committee (IBC) Coverpage for Biosafety Registration Form Principal Investigator: Dept: Phone: Alternate Contact: Phone: Please review the entire form prior to completion and provide information as requested and relevant to the biologicals in use and currently possessed by your laboratory. Registration of all your non-exempt (see NIH Guidelines) recombinant DNA constructs and your biohazardous materials with the IBC is required by the NIH. Be sure to save a copy on your computer for future modifications. For YES/NO questions, please place an X in the box next to the correct answer. Useful references are the NIH Guidelines for Research Involving Recombinant and Synthetic Nucleic Acid Molecules (NIH Guidelines) http://oba.od.nih.gov/rdna/nih_guidelines_oba.html, and the 5th edition of CDC/NIH Biosafety in Microbiological and Biomedical Laboratories  HYPERLINK "http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm" http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm, Questions can be referred to Harold Hoops ( HYPERLINK "mailto:Hoops@geneseo.edu" Hoops@geneseo.edu) or Kevin Militello (Militello@geneseo.edu). Sign and submit this document with any supporting attachments to the IBC in the Dept of Biology and as a PDF or Word e-mail attachment (Hoops@geneseo.edu).  Do you need to fill out a laboratory registration form? A. Does your research program currently involve possession and/or use of recombinant or synthetic nucleic acids that will be replicated in organisms (including bacteria)? (Note: modification and or replicating of nucleic acids exclusively in vitro is exempt.) YESNO B. Do you anticipate adding projects that require possession and/or use of recombinant or synthetic nucleic acids that will be replicated in organisms (including bacteria) in the near future? (Note: modification and or replicating of nucleic acids exclusively in vitro is exempt.) YESNO C) Does your research program currently involve biological toxins or organisms that fall under risk group 2, 3 or 4 of the NIH guidelines? (Risk group 2 agents are those that are associated with human disease which is rarely serious and for which preventative or therapeutic interventions are often possible. Risk groups 3 and 4 are for agents involved in more serious diseases. Contact the chairperson of the IBC and/or consult the NIH guidelines for more details.) YESNO D) Do you anticipate adding projects that involve biological toxins or organisms that fall under risk group 2, 3 or 4 of the NIH guidelines? YESNO If your answer to all of these questions is NO, please sign and date below. It is not necessary for you to fill out a laboratory registration form. However, if your lab decides to add research involving recombinant DNA, biological toxins or disease causing organisms be aware that you must fill out a laboratory registration form before initiating the projects. For some potential studies you must fill out the laboratory registration form in time for committee action BEFORE beginning the experiments. Principal Investigator: Date: If you answered YES to any of the four questions below, please fill out the full biosafety registration form.     Page  PAGE 1 of  NUMPAGES 1  PAGE 1 5_aa    D F G m n o L M ҽҲҤve^ hn5CJ!jhn5CJUmHnHuhn56CJh&nhn0JjhnUjhnUhhn0JjhhnUjhhnU)hhnB*CJOJQJ^JaJph hhnhn5B*ph hn5 hn>*CJ hnCJ hn6]hn#5_`a< = L N $$@&Ifa$l hc h^h`gdn$a$gdngdngdngdngdn w*./2446NV]`cdÿֱֿֿ֨֨֨|hth jh U h+?hnjhnUmHnHu h+hnh+hnCJ hn5CJ hn5CJhnho3hnCJh("hn6CJ hnCJhhn5CJ hhnhhn6CJhhnCJ/D?gdnkd~$$Ifl\( |L  064 la($$@&Ifa$l hc$$Ifa$l hc7kd@$$Ifl\( |L  064 la($$Ifa$l hc$$@&Ifa$l hc h^h`gdn$$Ifa$l hc$$@&Ifa$l hc h^h`gdngdn*./2k^^J7J$$Ifa$l hc$$@&Ifa$l hc h^h`gdnkd$$Ifl\( |L  064 la(2345645XKKKFgdn h^h`gdnkd$$Ifl\( |L  064 la($$Ifa$l hc56abcd h^h`gdnh^hgdn  h+?hnh htCJh4[t0JCJmHnHuht0JCJjht0JCJUh4[tmHnHuhtjhtU01h/R / =!`"`#`$`% DyK yK jhttp://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htmDyK yK 2mailto:Hoops@geneseo.edu$$If(!vh#vl#v#v#v:V l065555/  /  4a($$If(!vh#vl#v#v#v:V l065555/  /  4a($$If(!vh#vl#v#v#v:V l065555/  /  4a($$If(!vh#vl#v#v#v:V l065555/  /  4a("s666666666vvvvvvvvv666666>66666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH <`< NormalCJ_HmH sH tH >@>  Heading 1$$@&a$5<<  Heading 2$@&5CJBB  Heading 3$$@&a$5CJ<<  Heading 4$@&6CJHH  Heading 5$$@&a$ 56CJ]B@B  Heading 6$@& 56CJ]>>  Heading 7$$@&a$CJPDA`D Default Paragraph FontZi@Z  Table Normal :V 4 l4a _H(k (No List 2B@2 Body TextCJ6U`6 Hyperlink >*B*phFV F FollowedHyperlink >*B* ph6P"6 Body Text 2CJ424 Header  !HCBH Body Text Indent @ ^@ CJ@QR@ Body Text 3$a$5CJ4 @b4 Footer  !.)@q. Page Number0>@0 Title$a$5TRT Body Text Indent 2p^p`CJ^S^ Body Text Indent 3h^h` 56CJ]HH yb0 Balloon TextCJOJQJ^JaJN/N yb0Balloon Text CharCJOJQJ^JaJB' B O%0Comment ReferenceCJaJ88 O%0 Comment TextaJB/B O%0Comment Text CharCJaJHjH !O%0Comment Subject 5CJ\aJN/N  O%0Comment Subject Char5CJ\aJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VvnB`2ǃ,!"E3p#9GQd; H xuv 0F[,F᚜K sO'3w #vfSVbsؠyX p5veuw 1z@ l,i!b I jZ2|9L$Z15xl.(zm${d:\@'23œln$^-@^i?D&|#td!6lġB"&63yy@t!HjpU*yeXry3~{s:FXI O5Y[Y!}S˪.7bd|n]671. tn/w/+[t6}PsںsL. J;̊iN $AI)t2 Lmx:(}\-i*xQCJuWl'QyI@ھ m2DBAR4 w¢naQ`ԲɁ W=0#xBdT/.3-F>bYL%׭˓KK 6HhfPQ=h)GBms]_Ԡ'CZѨys v@c])h7Jهic?FS.NP$ e&\Ӏ+I "'%QÕ@c![paAV.9Hd<ӮHVX*%A{Yr Aբ pxSL9":3U5U NC(p%u@;[d`4)]t#9M4W=P5*f̰lk<_X-C wT%Ժ}B% Y,] A̠&oʰŨ; \lc`|,bUvPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!R%theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  * ===@  25 Fn XX*,18:@!!@ 2@H 0(  T1(  VB , C D"?\B 1 S Do"?B S  ?L  1H(Ht,|)t5>8              ()xT, " Jh6Ef K&`aTH7 ^`OJQJo( 8^8`OJQJo(^`OJQJ^Jo(o  p^ `OJQJo(  @ ^ `OJQJo( x^x`OJQJo(H^H`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(80^8`0o(. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.808^8`0o(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`o(. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.0^`0o(.^`. L ^ `L.  ^ `.xx^x`.HLH^H`L.^`.^`.L^`L.^`o(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.`aTT, KJh6E()hW        44D_                         bF4[tt \Nn @ @UnknownG.Cx Times New Roman5Symbol3. *Cx Arial3.Cx Times5. .[`)Tahoma?= *Cx Courier New;WingdingsA$BCambria Math"hXgXg G  &``r4 3qP?k 2!xx ,9University of Rochester Institutional Biosafety Committee Janet IvesPatricia Hamilton-Rodgers$      Oh+'0, P\ |   <University of Rochester Institutional Biosafety Committee Janet IvesNormalPatricia Hamilton-Rodgers2Microsoft Office Word@F#@}[@nA @nA  ՜.+,D՜.+,h$ hp  Home  :University of Rochester Institutional Biosafety Committee TitleT 8@ _PID_HLINKSA  :mailto:Hoops@geneseo.eduA5http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm  !"#$%&'()*+,-./012345678:;<=>?@BCDEFGHKRoot Entry F*΍ MData 1Table4WordDocument2*SummaryInformation(9DocumentSummaryInformation8ACompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q